BOT botanix pharmaceuticals ltd

Disagree with your analysis, when considering the discrepancy...

  1. 108 Posts.
    lightbulb Created with Sketch. 38
    Disagree with your analysis, when considering the discrepancy between US and AUS vehicles.
    When reviewing the AUS data alone, the primary endpoint data is statistically significant for inflammatory lesions.

    IF there had been no discrepancy, your analysis would stand.

    Unfortunately, the data is the data and BOT cannot discredit the US results (at this stage anyway), however they have clearly undertaken a root cause analysis and put a plan in motion to resolve for phase 3.

    Cheers,
    Sven
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
14.5¢
Change
-0.165(53.2%)
Mkt cap ! $284.3M
Open High Low Value Volume
27.0¢ 27.0¢ 13.0¢ $32.85M 195.8M

Buyers (Bids)

No. Vol. Price($)
12 598038 14.5¢
 

Sellers (Offers)

Price($) Vol. No.
15.0¢ 1084724 15
View Market Depth
Last trade - 16.12pm 08/07/2025 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.